Bone marrow of both normal and rearrangement-deficient mice contains a small population of B220(CD45R) + cells, which do not express the B lineage marker CD19. Instead, part of this population coexpresses the surface marker CD43 and lacks or expresses very low levels of heat stable antigen (HSA) and BP-1, thus representing a part of Hardy's fraction A (B220 +-CD43+HSA -, BP-1-) of B lineage development. However, some 20-40% of these B220 +-CD19-cells also coexpress the NKI.1 surface molecule and do not express genes like Vp~B or B29 restricted to the B cell lineage. These cells respond to recombinant interleukin 2 in vitro, and develop into killer cells that can lyse the prototypic NK target tumor cell, YAC-1, as well as syngeneic nomaal lipopolysaccharide or concanavalin A blasts, providing they lack the surface expression of major histocompatibility complex class I molecules. The implications of these findings for studies on B lymphopoiesis are discussed. It is suggested that the CD19-specific monoclonal antibody is more reliable, as in humans, than B220(CD45R) to detect B lineage cells in mice.
I
n the mouse, B lineage cells express the surface marker .B220(CD451L) (1) . From the earliest identified c-kit + pro-B cell in fetal liver and bone marrow, all the way through the mature slgM+slgD + peripheral B cell as well as activated B cell blasts, all B lineage cells express the B220 marker often in upregulated forms. Only at the latest stage of B cell development, the fully differentiated plasma cell, is B220 downregulated. Even in recombinase-deficient (SCID and RAG-T) mice, the B220 surface marker is expressed on early progenitors (2) (3) (4) . Therefore, B220(CD45R) is commonly used as a pan-B cell marker for studies in the mouse. In humans, however, another cell surface molecule, CD19, is used as a pan-B cell marker, since reagents specific for a possible B220-1ike isoform of human CD45R do not exist (5, 6) . We have used a newly generated mAb specific for murine CD 19 to compare the expression of B220 with that of CD19 on cells of bone marrrow of normal as well as of rearrangement-deficient (RAG-2T) 1 animals. We identify IAbbreviations used in this paper: BDF, (C57BL/6 X DBA/2)FI: J3:mT mice, B 2 microglobulin-deficient nfice; HSA, heat stable antigen; RAG-2T mice, recombinase-activating gene 2-deficient nfice; RT, reverse transcriptase.
here a fraction of bone marrow B220 + cells that does not express CD19 and does not belong to cells committed to the B lineage, but that has both phenotypic and functional properties of NK cell precursors.
Materials and Methods
Mice. 4-5-wk-old fen~tle BALB/c, C57BL/6 and (C57BL/6 X DBA/2)F1 (BDF0 mice were purchased from Biological Research Laboratories, Ltd. (Ftillinsdorf, Switzerland). RAG-2T mice (4) originally obtained from Dr. F. Alt (The Children's Hospital, Boston, MA) and B 2 microglobulin~deficient (B2MT) mice (7) originally obtained from Dr. R. Jaenisch (Massachusetts Institute of Technolog% Cambridge, MA) were bred in our own animal facilities.
Antibodies. The FITC-, PE-and APC-labeled mAb RA3.6B2 (anti-CD45R, B220), the biotin-, FITC-or PE-conjugated mAbs 145-2C1 l (anti-CD3-e-chain), RM4-5 (anti- (9) , and 1D3 (anti-CD19, see below) are lgG of rat origin and were purified from hybridoma culture supematants on protein G-Sepharose columns (Pharmacia, Uppsala, Sweden) as recommended by the supplier. They were FIT(] or biotin labeled according to standard procedures. FITC-conjugated goat anti-mouse lgM and streptavidin-PE were purchased from Southern Biotechnology Associates (Birmingham, AL).
Production qf Anti-CD I 9 mAbs. The human erythroleukemia cell K562 was transfected (10) with expression vector pZipNeo containing the full-length eDNA encoding murine CD19 (11). G418-selected K562 cells expressing high levels ofmurine CD19 were used to irmnunize Lewis rats, from which hybridomas were produced after fusion of splenocytes with NS-1 myeloma cells following standard procedures. One clone, 1D3, is a rat IgG2~K and was selected for its ability to bind murine CDl9-transfected K562, but not wild-type K562, cells. The antibody inununoprecipitates the expected protein of 110 kD from transfected cells (12) .
Flow Cytometry. Flow cytometric analyses were performed as described below (13, 14) . For cell sorting, bone marrow cells were stained with APC-labeled B220 together with biotinlabeled anti-CDl9 revealed by PE-streptavidin. Stained cells were resuspended in PBS containing 2% FCS and 1 lxg/ml propidium iodide (Sigma Chemical Co., St. Louis, MO) to exclude dead cells by gating in FL3 as described (15) . Sorted cells were either used tbr in vitro cell culture or for further flow cytometric analyses. For in vitro cell culture, B220+NKl.1 § B220*CD4 +, and B220+CD19 NKI.I CD4-cell populations were sorted. Therefore, bone marrow cells were stained with FITC-labeled anti-B220 together with either PE-conjugated anti-NKl.1, PEconjugated anti-CD4, or a cocktail of PE-conjugated anti-NK1, l, anti-CD4, and anti-CD 19. Sorted cell populations were routinely reanalyzed and showed >95% purity in all experiments showed herein. Cell sorting was performed on a FACStar | (Becton Dickinson & Co., Mountain View, CA), while a FACScan '~ (Becton Dickinson & Co.) was used tbr flow cytometric analyses.
Cell Culture and Generation qf LdK Cells. All cell cultures were performed using IMDM (GIBCO-BP,,L, Life Technologies Ltd., Paisley, Scotland) containing 1• nonessential anfino acids, 1• kananwcin (both from GIBCO-BILL), 5 • 10 -5 M [3-mercaptoethanol (Fluka AG, Buchs, Switzerland), 5 txg/ml porcine insulin (Sigma Chemical Co.), 0.03% Primatone P,L (Quest Interuational, Naarden, The Netherlands), and 2% FCS (GIBCO-BR.L) as described earlier (16) . For the generation of LAK cells, sorted cells were plated at l0 s cells/ml m 1 nil culture medium supplemented with 103 U/nil of rlL-2 obtained from a transfected X63-Ag8.653 cell line (17) generated in our laboratory. After 5 d of culture, cells were harvested, washed, and counted for subsequent use either in FACS analyses or 5~Cr release assays. The recovery, of rIL-2-activated NK1.1-cells after 5 d was generally 1{>20 times the number of input cells.
Preparation qf NK Targets and S~Cr Releaser Assay. Target cells from nomaal or 13~mT mice were prepared by culturing spleen cells at 106 cells/ml in the presence of 2 btg/ml of Con A (Pharmacia) or 20 ~g/nfl of LPS (from Escherichia coli EH100, kindly provided by Dr. C. Galanos, Max Planck Institute tbr hnmunobiology, Freiburg, Germany). After 2 d, the cells were harvested and enriched for viable blast cells by centrifugation onto a cushion of Ficoll-Paque (Phamlacia) according to the instructions of the manufacturer. Spleen cell blasts as well as YAC-1 Moloney leukemia virus-induced lymphoma cells (18) were adjusted to 1{) 7 cells/nil in medium containing FCS, of which 100 I~1 was labeled with 1 mCi ofsodium-Slchromate (CJS 4, sp. act. 12.5 GBq/mg; Amersham Life Science, Amersham, UK) tbr 2 h at 37~ (19) . Atier three washes with prewarmed medium, labeled target cells were counted and concentrations adjusted to l0 s cells/ml. Target cells were distributed in 50-1xl aliquots (5,000 targets/well) into wells of V-bottom microtiter plates, which previously had received 50-btl replicas containing twofold dilutions in medium of effector cells so as to obtain different E/T cell ratios. To allow immediate contact between targets and effector cells, plates were spun for 1 rain at 1,000 rpm followed by a 4-h incubation period at 37~ After incubation, plates were spun at 1,200 rpm for 5 min, and 50 txl of supernatant was aspirated for counting in a ganuna counter (Cobra 5010; Packard Instrument Company, Meriden, CT). Specific lysis was calculated as % specific lysis = (E -S)/ (T -S) • 100, where E was the experimental StCr release, S was the count released when target cells were cultured alone, and T was the total counts contained in the target. SD of triplicate sampies never exceeded 2.5%.
Limiting (23): 5' ACC GAT GCT GAC CTG GGC CTC 3', 5' AGG TTC CTG AGG CCT GAC CGC 3'. Amplification of the cDNA was carried out with 1 cycle at 94~ for 30 s followed by 3{) cycles at 94~ for 20 s, 55~ tbr 20 s, and 72~ for 60 s. The expected sizes of the PCt~-products are 535 bp fbr [3-actin, 400 bp fbr VpreB , 320 bp fbr B29, and 610 bp for perforin. P,T-PCR products were electrophoresed through a 1% agarose gel and visualized by UV light after ethidium bromide staining. In addition, after electrophoresis, the products of the perforin PCR. were analyzed by Southern blotting after transfer to a Genescreen Plus (NEN Dupont, Boston, MA) membrane in 0.4 M NaOH. After neutralization with 0.2 M phosphate butter (pt-I 7.2) and prehybridization at 42~ for 4 h, the membranes were hybridized at 42~ overnight with a ~2P-labeled oligonucleotide probe (protocol and probe kindly provided by Dr. H.-P-. 1Lodewald, Basel Institute for lmmunolog3', Basel, Switzerland). Both prehybridiza-tion and hybridization were performed in 4 • SSC, 1 • Denhart's solution, and 0.1% SDS. Membranes were washed four times in 4 • SSC, 0.1% SDS, at 42~ for 10 min and exposed to x-ray film (X-OMAT; Eastman Kodak Co., Rochester, NY).
Results and Discussion
The Expression of B220(CD45R) and CD19 on Mouse Bone Marrow Cells. A mAb recognizing mouse CD19 has been used to identify cells in the mouse bone marrow that express this B lineage-related surface marker. Double staining, together with an antibody directed against the other mouse B lineage-related surface marker B220(CD45R), identified three populations in FACS | analyses of normal BDF 1 bone marrow: B220-CD19-cells, B220+CD19 + ceils, and B220+CD19 -cells. No B220-CD19 + cells could be detected by FACS | analyses (Fig. 1) . The B220+CD19 + cells in normal mouse bone marrow contain all the cells belonging to different stages of B cell development, that is, c-kit+CD43+CD25 -pro-pre-B-I cells (14) , c-kit-CD25 + pre-B-II cells (24, 25) , sIgM+IgD -immature B cells, and sIgM+IgD + mature B cells (26) (data not shown). Thus, all B lineage-committed cells in normal bone marrow identified so far express both B220 and CD19.
In bone marrow of RAG-2T mice, the same three populations are found: B220-CD19-cells, B220+CD19 + cells, and B220+CD19 -cells (Fig. 1) . Again, no B220-CD19 + cells could be detected, as in normal bone marrow. The B220+CD19 + fraction of cells in RAG-2T mice is reduced in size compared with bone marrow of normal mice, which is in agreement with a block of B cell differentiation at the transitional stage from pro/preB-I to pre-B-II cells due to the rearrangement deficiency. The size of the B220+CD19 -fraction of cells in the RAG-2T bone mar-
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RAG-2 H- row was determined and compared with that of normal mice. Therefore, bone marrow cells pooled from five RAG-2T mice and five age-matched normal mice at different times after birth (4, 10, and 15 wk) were analzyed. In all samples, independent of age and strain, 3-6% of all nucleated bone marrow cells were B220+CD19 -(data not shown).
Analysis of the Function(s) of B220 § CD 19-Cells in Mouse Bone
Marrow. It appeared reasonable to expect that the B220+CD19 -cell fraction in bone marrow (Fig. 1) could contain earlier B lineage precursors, before the expression of CD19. Therefore, we used culture conditions similar to those used for cloning and long-term proliferation of pro-pre-B-I cells (16) , that is, a layer of stromal cells and added recombinant cytokines, in an attempt to convert the B220+CD19 -cells to B220+CD19 + stromal cell/IL-7- and subjected to cell sorting as described in Materials and Methods. The sorted cells were restained and analyzed by FACScan | for the surface markers CD43, CD24 (HSA), BP-I, and NK1.1, as described in Materials and Methods. Since the restaining was done using biotinylated antibodies revealed by streptavidin-PE, the control graphs indicate background staining with PE-streptavidin only.
reactive pre--B-I cells (27) . rIL-2, rIL-3, rlL-4, rIL-5, rIL-6, rlL-7, and rlL-10 were tested in these experiments (17) . IL-3, IL-5, [L-6, IL-7, and IL-10 did not change the phenotype or reactivity of the B220+CD19 -cells in the expected way. However, to our surprise, ceils in cultures containing rlL-2 or rlL-4 within 5 d developed into apparent killer cells, destroying the coculture stromal cells. This occurred with B220+CD19 -cells from bone marrow of both normal and RAG-2T mice, excluding the participation of conventional cytotoxic T killer cells. This prompted an examination of the expression of additional markers on sorted B220+CD19 -bone marrow cells. In Fig. 2 , part of the extra markers expressed on B220 +-CD19-cells in the bone marrow of BDF 1 and RAG-2T mice are shown. In both strains, these cells express CD43 but not or only low levels of CD24 (HSA) and no BP-1 (Fig. 2) and therefore might contain cells defined by Hardy et al. (28) as fraction A in their scheme of B cell development. About 20-40% of the B220+CD19 -cells in the bone marrow of both BDF 1 and RAG-2T mice express the NK cell-related marker NK1.1 (29) . This marker is not detectable on the B220+CD19 + cells (data not shown). The number of B220+NKI.1 + cells was in several experiments slightly higher (maximally twofold) in RAG-2T mice compared with age matched normal mice (see Fig. 2 ).
Sorting the B220+CD19-NK1.1 + and the B220+CD19 --NK1.1-populations and subsequently analyzing their IL-2 reactivity revealed that only the B220+CD19 NK1.1+, but not the NKI.I-, cells developed into killer cells (see below). The B220+CD19-NK1.1 + cells lack the expression of CD25 (the IL-2 receptor ot chain), but do express CD122 (the IL-2 receptor 13 chain).
After culture in rlL-2, these cells remain B220+CD19 --NKI.1 +, but lose the expression of CD43 (Fig. 3) . They are homogeneously large and granular as revealed by forward and sideward scatter analyses. All these cells coexpress the newly described NK cell surface marker 2B4 (30) and low levels of CD122 (IL-2R 13 chain), but not CD25 (IL-2R o~ chain). A fraction of the cells express Mac-1 and another NK cell surface marker, 5E6 (31) . In the bone marrow of normal mice, a fraction of the B220+CD19 --NKI.1 + cells coexpress CD3~, and their relative number stays constant during culture in rlL-2. Since no CD3~-expressing B220+CD19-NKl.1 + cells are present in the bone marrow of RAG-2T mice, these cells most likely represent the previously described NKI.1 + T cells (32, 33) .
We conclude that by marker expression and morphology these activated B220+CD19-NKl.1 + bone marrow cells are similar to NK cells found in the periphery and classified as LGL (34) . It has been shown previously that stimulation of spleen cells with IL-2 (35) or IL-4 (36) may generate lytically active NKI.1 + cells that coexpress B220. However, fresh ex vivo, sorted B220+CD19-NKl.1 + bone marrow cells do not cause lysis of the stroma cells in a short-term assay, nor do they kill classical NK targets, like YAC-1 (see below). We were concerned that the anti-NKl.1 mAb (PK136) used for sorting these cells would inhibit spontaneous killer activity, as has been reported previously (37) . Therefore, freshly isolated total bone marrow cells from RAG-2T animals were used in the standard 51Cr release assay. At E/T cell ratios up to 300:1 we observed no significant lysis of YAC-1 tumor cells, in accordance with previously published data (38, 39) . Also, in assays with rlL-2-activated NKI.1 cells, addition of up to 100 fxg/ml of PK136 mAb would not inhibit lysis of YAC-1 tumor targets or normal LPS-or Con A-activated blasts of 132mT origin. We emphasize, though, that we used bone marrow of healthy, unmanipulated mice, whereas most other investigators demonstrating NK activity of cells freshly isolated ex vivo used spleen cells from animals pretreated with interferon inducers like polyinositol:polycytidine (37) or tilorone (40) . It therefore appears that the 5-d cell culture period in the presence of rIL-2 or rlL-4 differentiated NK activity from more undifferentiated, inactive precursor cells. Currently the potential of these cells is analyzed by "in vivo" transfer systems.
The B220+CD19-NK1.l-CD4 -population might contain some early B cell progenitors, since preliminary RT-PCR analyses revealed low expression of ks, VwB, rob-1, and B29 genes in these cells (data not shown). Moreover, limiting dilution experiments showed that 1/100 to 1/200 of these cells can form pre-B cell colonies in the presence of rlL-7. Also, the potential of these cells is currently being analyzed by in vivo transfer systems.
Most NK1. I +B220 + CD 19-Cells Are Precursors of Classical NK Cells and Respond to IL-2 by Development into Clones of Cytolytic NK Cells. Classical NK cells kill MHC class
I-target cells (40, 41) , and are inhibited in their killing activity by the expression of MHC class I molecules on target cells (42) . Therefore, a variety of LPS-or Con A-activated spleen cells were used as targets in 51Cr release cytotoxicity assays. Syngeneic, semisyngeneic, or allogeneic targets from normal mice were not significantly lysed by these rlL-2-activated NKI.1 + cells at E/T ratios of 10:1 and below. However, when Con A-or LPS-activated targets were generated from [32mT mice lacking MHC class I surface expression, syngeneic and allogeneic targets were lysed to the same extent irrespective of whether the targets were of T or B cell origin, often reaching 30--60% specific lysis at E/T ratios of I : 1 during the 4-h assay period (Fig. 5 a) . Always included in the 51Cr release assays was the prototypic NK target YAC-1, which typically showed 60-80% spe- cific lysis at similarly low E/T ratios. The fact that we observe a plateau of specific lysis different for the tumor target compared with the splenocyte targets may be due to our way of calculating the percentage of specific lysis: the total cpm of SlCr contained within the targets was used rather than attempting to determine total counts releasable by artificial means using agents like SDS, NP-40, or acetic acid. These results support the conclusion reached by analysis of NKI.1 expression that the cytotoxic activity developed from B220+CD19-NKl.1 + cells of bone marrow is conveyed by NK cells. Since only 60-80% specific SlCr release could be obtained in the cytotoxic assay using YAC-1 as a target, we devised a method to determine the viability of the tumor target cells by a test that measures their growth after contact with the effector cells. . Expression of mRNA for VpreB , B29, and perforin in sorted B220+CD19 +, B220+CD19-NK1.1 +, and rlL-2-stimulated B220 +CD 19-NK1.1 + cells from bone marrow of RAG-2T animals. Total RNA isolation and RT-PCR assays were performed as described in Materials and Methods. Different dilutions of cDNA were subjected to PCR amplification specific for ~-actin, VpreB , B29, and perforin. Dilutions of the resulting products were separated by electrophoresis on a 1% agarose gel containing ethidium bromide and visualized by UV light illumination (A). In addition, the products of the PCR assay for perforin were blotted and hybridized with an internal probe of the following sequence: 5' AGG CCA GAG GCA AAC ATG CG 3' specific for perforin (B).
R N A was extracted from fleshly sorted as well as cultured cells. Subsequently, expression of m R N A for VpreB, B29, and perforin was analyzed by R T -P C R . A variety of oligonucleotide primers spanning an i n t r o n -e x o n boundary described in Materials and Methods were used. As can be seen in Fig. 6 , only the B220+CD19 + and not the B220+CD19 --NK1.1 + or the rlL-2-activated B220+CD 19-NK1.1 + cells express the B cell lineage marker Vere/3 and B29 genes, whereas only rlL-2-activated, not freshly isolated NK1.1+, cells express abundant levels of perforin m R N A , a distinguishing marker for mature cytolytic T and N K cells (23) .
Conclusions.
The data presented here show that not all B220 + cells belong to the B cell lineage. Within the B220+CD19 -cells at least three subpopulations can be distinguished. The first, expressing NKI.1, has been identified here in detail to be the precursor of N K cells. This cell is likely to be a product of an earlier N K I . 1 -precursor, which, upon transplantation, develops into NKI.1 § cells capable of hybrid resistance (43) . The second, expressing CD4, has a potential and/or function that is so far u nknown. Within the third group of cells, which are N K I . I -C D 4 -, are those that, upon culture on stromal cells and IL-7, form pre-B colonies. Precursors for other blood cell lineages might also be contained within this group of cells, but attempts to clone them with the appropriate cytokines have so far failed. All of these B220 + subpopulations of cells express CD43 and are low or negative for HSA and BP-1 expression, markers that define fraction A in Hardy et al.'s (28) scheme of B cell differentiation.
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